Treatment progress of relapsed and refractory Hodgkin lymphoma

VernacularTitle:复发难治性霍奇金淋巴瘤治疗研究进展
Author: Bihui PAN ¹ ; Huayuan ZHU ; Wei XU
Author Information

1. 210029,南京医科大学第一附属医院江苏省人民医院血液科
Keywords: Lymphoma; Hodgkin; Recurrence; Refractory
From: Journal of Leukemia & Lymphoma 2018;27(1):24-27
CountryChina
Language:Chinese
Abstract: Hodgkin lymphoma (HL) is a highly curable malignancy for most patients, while the treatment of relapsed and refractory HL is still a difficult and important field. A high dose of chemotherapy with autologous stem cell transplantation is treated as the preferred treatment with a high relapse incidence. The 59th American Society of Hematology Annual Meeting reported the recent progress of the treatment of relapsed and refractory HL, including the improvement of traditional high dose chemotherapy regimens, the new drugs or therapies like brentuximab vedotin, nivolumab, pembrolizumab and ibrutinib, and chimeric antigen receptor T-cell. This review focuses on these advances.